SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 51.59-1.1%Dec 2 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: keokalani'nui who wrote (3012)2/27/2001 10:44:51 PM
From: Biomaven  Read Replies (1) of 52153
 
Actually AZN does have a very nice pipe. Here's a description (not sure what the date of this is):

astrazeneca.com

Of course they have a mighty big ($4 billion?) hole to fill when omeprazole (Prilosec) loses patent protection next year in the US, with another few billion to go when it loses patent protection worldwide. They just got FDA approval last week for Nexium, their chiral switch. It's probably marginally better than Prilosec, although I haven't seen the label yet. (My view is that most of the reason it did somewhat better than Prilosec in their studies is that they tested against 20mg/day Prilosec instead of 40mg/day).

Bottom line is that next couple of years will be pretty marginal growth-wise, but things should pick up later.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News